ArticleClinical transplantation2019
Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers.
Article in Clinical transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Skin Cancer in Solid Organ Transplant Recipients: A Review.American journal of clinical dermatology · 2026Review
- Influence of Extended Itraconazole Antifungal Prophylaxis on the Development of Fungal Infections After Lung Transplant.Journal of transplantation · 2026Article
- Creation of an ultra-sensitive and specific molecularly imprinted polymer sensor with ZnO nanoparticle assistance for valganciclovir detection.Mikrochimica acta · 2025Article
- Non-JHLT open · 2025Review
- Role of liposomal amphotericin B in intensive care unit: an expert opinion paper.Journal of anesthesia, analgesia and critical care · 2025Review
- Review
- Invasive candidiasis following lung transplant: An Assessment of impact utilizing a national insurance claims cohort.PloS one · 2025Article
- Bridging Echinocandin With Azole Antifungal Therapy on Prevention of Invasive Candidiasis Post-Lung Transplantation.Open forum infectious diseases · 2024Article
- Fungal Infections and Colonization after Bilateral Lung Transplant: A Six-Year Single-Center Experience.Journal of fungi (Basel, Switzerland) · 2024Article
- Invasive Aspergillosis among Lung Transplant Recipients during Time Periods with Universal and Targeted Antifungal Prophylaxis-A Nationwide Cohort Study.Journal of fungi (Basel, Switzerland) · 2023Article
- Long-term management and outcome of lung transplantation in Japan.Journal of thoracic disease · 2023Review
- Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model.Antibiotics (Basel, Switzerland) · 2023Article
- Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges.Journal of fungi (Basel, Switzerland) · 2023Review
- Adverse Events Associated with Universal versus Targeted Antifungal Prophylaxis among Lung Transplant Recipients-A Nationwide Cohort Study 2010-2019.Microorganisms · 2022Article
- Nationwide survey of infection prevention protocols in solid organ transplantation in South Korea.Korean journal of transplantation · 2022Article
- Medical Complications of Lung Transplantation.Journal of chest surgery · 2022Article
- Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.Journal of fungi (Basel, Switzerland) · 2022Review
- Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Review
- Fungal infections in lung transplantation.Journal of thoracic disease · 2021Review
- Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAntifungal prophylaxis strategies for lung transplant recipients vary without consensus or standard of care. Our current study aims to identify antifungal prophylaxis practices in the United States.
methodsFrom November 29, 2018, to February 15, 2019, we emailed surveys to medical directors of adult lung transplant centers. An alternate physician representative was approached if continued non-response after three survey attempts. Descriptive statistics were used to report findings.
resultsForty-four of 62 (71.0%) eligible centers responded. All Organ Procurement and Transplantation Networks were represented. Only four (9.1%) centers used pre-transplant prophylaxis for prevention of tracheobronchitis (3 of 4) and invasive fungal disease (4 of 4). Thirty-nine of forty (97.5%) centers used post-transplant prophylaxis: 36 (90.0%) universal and 3 (7.5%) pre-emptive/selective prophylaxis. Most centers used nebulized amphotericin with a systemic agent (26 of 36, 72.2%). Thirty-two of thirty-six (88.9%) centers continued universal prophylaxis beyond the hospital setting. Duration of prophylaxis ranged from the post-transplant hospitalization to lifelong with most centers (25 of 36, 69.4%) discontinuing prophylaxis 6 months or less post-transplant.
conclusionMost United States' lung transplant centers utilize a universal prophylaxis with nebulized amphotericin and a systemic triazole for 6 months or less post-transplant. Very few centers use pre-transplant antifungal prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.